Success Metrics

Clinical Success Rate
87.5%

Based on 14 completed trials

Completion Rate
88%(14/16)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
2(13%)

Phase Distribution

Ph phase_2
1
6%
Ph phase_3
15
94%

Phase Distribution

0

Early Stage

1

Mid Stage

15

Late Stage

Phase Distribution16 total trials
Phase 2Efficacy & side effects
1(6.3%)
Phase 3Large-scale testing
15(93.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(14)
Terminated(2)

Detailed Status

Completed14
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
87.5%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (6.3%)
Phase 315 (93.8%)

Trials by Status

completed1488%
terminated213%

Recent Activity

0 active trials
Showing 5 of 16
terminatedphase_3

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

NCT00434096
terminatedphase_3

Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

NCT00678483
completedphase_3

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

NCT00124332
completedphase_3

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients

NCT00481923
completedphase_3

Obese Patients With or Without Comorbidities (RIO-North America)

NCT00029861
View all 16 trials

Clinical Trials (16)

Showing 16 of 16 trials
NCT00434096Phase 3

Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)

Terminated
NCT00678483Phase 3

Long-Term Effect of 10 mg Versus 20 mg Rimonabant in Overweight or Obese Patients

Terminated
NCT00124332Phase 3

STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)

Completed
NCT00481923Phase 3

Efficacy and Safety of Rimonabant With or Without Hypocaloric Diet in Obese Patients

Completed
NCT00029861Phase 3

Obese Patients With or Without Comorbidities (RIO-North America)

Completed
NCT00458718Phase 3

Efficacy and Safety of Rimonabant as an Aid to Smoking Cessation With or Without Nicotine Patch

Completed
NCT00029835Phase 3

Obese Patients With Untreated Dyslipidemias

Completed
NCT00386061Phase 3

Rimonabant in Obesity Over a 2-Year Duration (RIO-Europe)

Completed
NCT00029848Phase 3

Obese Patients With Type 2 Diabetes

Completed
NCT00257257Phase 3

Study Evaluating Rimonabant Efficacy in Drug-NAive DiabEtic Patients

Completed
NCT00325546Phase 3

Study of Weight-Reducing Effect and Safety of Rimonabant In Obesity in ASIA (RIO-ASIA)

Completed
NCT00459004Phase 2

Japanese Dose-Response Study of Rimonabant in Obese Patients

Completed
NCT00481975Phase 3

Efficacy and Safety of Rimonabant on Weight Loss and Frequency of Binge Episodes in Obese Patients

Completed
NCT00459173Phase 3

Efficacy and Safety of Rimonabant as an Aid to Maintenance of Smoking Cessation

Completed
NCT00239967Phase 3

An International Study of Rimonabant in Dyslipidemia With AtheroGenic Risk In Abdominally Obese Patients

Completed
NCT00288236Phase 3

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16